We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

CHEMBIO DIAGNOSTIC SYSTEMS

Chembio develops, manufactures and commercializes diagnostic solutions and products for the rapid and early detection... read more Featured Products: More products

Download Mobile App




Rapid Tests Conclusively Diagnose Chagas Disease

By LabMedica International staff writers
Posted on 19 Apr 2017
Chagas disease is caused by infection with the Trypanosoma cruzi that are generally transmitted by triatomine vectors that are endemic to the Americas. More...
It affects several million people and severe cardiac and/or digestive complications occur in about 30% of the chronically infected patients.

In recent decades, population movements from endemic to non-endemic regions and the chance of vector-independent transmission have globalized the disease impact to non-endemic countries like Spain. The acute stage of the disease is mostly asymptomatic and infection goes undiagnosed. In the chronic phase direct parasite detection is hampered due to its concealed presence and diagnosis is achieved by serological methods.

Scientists working with those at the Barcelona Institute for Global Health carried out a prospective study and took 342 blood samples from 223 women and 119 men living in an endemic region of Bolivia. Sampling was made between March and May 2014. The study was a double-blind with three different observers involved: two for each of the rapid diagnostic test (RDT), and a third one for the conventional serological tests (indirect hemagglutination assay (IHA), enzyme linked immunosorbent assays (ELISA), based on lysate antigen, and ELISA based on recombinant antigen.

The team used serodiagnosis, first by rapid screening with the RDT Chagas Stat-Pak. A second RDT, Chagas Detect Plus was also used in parallel. In order to qualify a rapidly diagnosed positive patient for treatment, conventional serological confirmation is obligatory. The ELISA tests were from Wiener Lab and included the parasite lysate-based ELISA.

The performance of CST and CDP was identical. The comparison with the conventional serology results yielded exactly the same results, either evaluating them individually or as a duo. Their reported sensitivity was 100% whereas specificity was 99.3%. RDTs positive predictive value was 99.5%, and their negative predictive value was 100%. In comparison with the three conventional serological tests, each RDT detected the same single false positive patient that was shown to be negative in all three conventional serology tests.

The authors concluded that their study validates the use of the CST and CDP diagnostic duo to reduce response time to patients and the logistic resources currently needed to elaborate a confirmed Chagas disease diagnosis. Therefore, they encourage considering the implementation of both RDTs with whole blood as sample to provide fast, reliable and definite diagnosis of Chagas disease in distant settings. The study was published on April 3, 2017, in the journal Public Library of Science Neglected Tropical Diseases.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Age-Based Genetic Testing May Miss Most Inherited Cancer Risk Variants

Inherited cancer risk can influence diagnosis, treatment planning, and family screening, yet current testing practices often depend on a patient’s age at diagnosis. Many patients undergo germline genetic... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.